January 25, 2018 / 9:19 PM / 6 months ago

BRIEF-Alnylam Announces EMA Acceptance Of Marketing Authorisation Application For Patisiran

Jan 25 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION (MAA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

* ALNYLAM PHARMACEUTICALS- UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY HAS GRANTED DESIGNATION OF PATISIRAN AS A PROMISING INNOVATIVE MEDICINE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below